General Information of Drug (ID: DM6XEQA)

Drug Name
PF-610355 Drug Info
Synonyms PF-00610355; Beta 2 adrenoceptor agonist (asthma), Pfizer
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
11505444
CAS Number
CAS 862541-45-5
TTD Drug ID
DM6XEQA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indacaterol DMQJHR7 Chronic obstructive pulmonary disease CA22 Approved [3]
Formoterol DMSOURV Allergic asthma CA23.0 Approved [4]
Salbutamol DMN9CWF Acute asthma CA23 Approved [5]
Arformoterol DMYM974 Chronic obstructive pulmonary disease CA22 Approved [6]
Isoproterenol DMK7MEY Atrioventricular block Approved [7]
Salmeterol DMIEU69 Allergic asthma CA23.0 Approved [8]
Clenbuterol DMCKYZ5 Chronic breathing disorder 7A4Z Approved [9]
Ritodrine DM4V6RL Premature labour JB00 Approved [10]
Olodaterol DM62B78 Chronic obstructive pulmonary disease CA22 Approved [11]
Fenoterol DMIP3ZV Asthma CA23 Approved [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Agonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025582)
2 Inhalation by design: novel ultra-long-acting beta(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem. 2010 Sep 23;53(18):6640-52.
3 Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
4 Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
5 Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
6 Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
7 Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
8 Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
9 Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
12 Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.